Form 4: Vaxcyte COO Sells Shares Under 10b5-1 Plan

Vaxcyte, Inc. (PCVX) Chief Operating Officer Jim Wassil reported transactions involving the sale of company stock under a pre-arranged trading plan.

Summary

• Jim Wassil, Chief Operating Officer of Vaxcyte, Inc., executed a series of stock transactions on July 1, 2026.
• These transactions included the acquisition of 516 shares of common stock at a price of $5.35 per share.
• Additionally, Wassil disposed of a total of 2,250 shares of common stock through multiple sales at weighted-average prices ranging from $55.60 to $57.82.
• The sales were conducted under a Rule 10b5-1 trading plan adopted on December 9, 2025, which is designed to comply with affirmative defense conditions for insider trading.
• Following these transactions, Wassil beneficially owns 156,760 shares of common stock directly.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider selling activity, despite the use of a 10b5-1 plan. The volume of shares sold by a key executive warrants attention.

Positives

• The transactions were executed under a Rule 10b5-1 plan, indicating pre-planned and potentially non-insider-trading-related sales.
• The acquisition of 516 shares at a lower price point ($5.35) could represent an option exercise or a purchase at a favorable rate.

Negatives

• The disposal of a significant number of shares (2,250) by a key executive could be perceived negatively by the market.
• The sales occurred at prices significantly higher than the acquisition price, suggesting the executive is realizing gains.

Risks

• Potential for negative market perception due to insider stock sales, even if conducted under a 10b5-1 plan.
• The weighted-average pricing for sales indicates a range of prices, which could lead to varied investor interpretations.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025.
• The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Industry Context

StockSavvy.ai notes that insider sales, even under a 10b5-1 plan, are closely watched by investors. The adoption of such plans is a common practice to allow executives to diversify holdings or manage personal finances without triggering insider trading concerns, but the volume and timing of sales can still influence market sentiment.

Stakeholder Impact

• Shareholders may interpret the sales as a signal of reduced confidence by management, potentially impacting share price.
• The company's management team may face increased scrutiny regarding their stock holdings and trading activities.

Next Steps

• The reporting person may provide further details on individual sale prices upon request from the SEC, issuer, or security holder.

Key Dates

Recommendation

The filing reports routine insider transactions under a pre-established plan, which is standard practice. While insider selling can be a negative signal, the structured nature of the sale via a 10b5-1 plan mitigates immediate concern. Investors should monitor the company's overall performance and future filings for more significant indicators.

Keywords

Vaxcyte, PCVX, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Jim Wassil, Chief Operating Officer, Beneficial Ownership, Securities Exchange Act